Latest Content

Patient selection raised detection of pathogenic germline variants from 6% to 27% in lung cancer studies.

Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.

Prescription Wellness unites providers and payers with EMR-integrated referrals, boosting patient engagement and coordinated support for chronic, behavioral, and social needs.

Leaders from Boehringer Ingelheim, Incyte, Pfizer, and Takeda told the audience at Patient-Centered Oncology Care® that artificial intelligence (AI) is compressing discovery timelines, but that gaps in testing, data, and community access still decide which patients benefit.

Many patients who stop a GLP-1 RA regain weight. How plans can measure adherence when cash-pay fills go unseen.

Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.

In more than 250,000 adults with prediabetes and obesity, GLP-1 users had lower risks of type 2 diabetes, death, and cardiovascular events.

Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.

The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).